Mashhadi Mohammad Ali, Heidari Zahra, Zakeri Zahra
Genetics of Noncommucable Genetic Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Iran J Kidney Dis. 2013 Jan;7(1):23-7.
Cisplatin still has a central role in cancer chemotherapy, but is associated with the risk of toxicities, the most common of which is nephrotoxicity. The aim of the present study is evaluation of cisplatin nephrotoxicity in Iranian population of cancer patients.
All admitted patients to the oncology service who received cisplatin were included in a prospective study from 2004 to 2010. Clinical and laboratory data including kidney function tests were recorded at baseline and during follow-up visits.
One hundred patients (56% men) were included. Their mean age was 44 years. Common adverse events were nausea (85%) and vomiting (78%), followed by anorexia and fatigue (20%), taste change (10%), hearing loss (8%), cramping abdominal pain (8%), and tinnitus (5%). The most important finding was normal kidney function, except for mild hypomagnesemia (grade 1 toxicity) in 18%, without any symptoms or other electrolyte abnormalities. None of the patients with hypomagnesemia had significant serum electrolyte imbalances, diarrhea, severe allergic reactions, difficulty in walking, or chest pain.
Cisplatin has the potential to produce both mild and severe side effects. Although the neurologic and gastrointestinal toxicities were observed, renal toxicity (rising blood urea and creatinine or electrolyte abnormality) was not observed, and the only toxicity was grade 1 hypomagnesaemia.
顺铂在癌症化疗中仍起着核心作用，但与毒性风险相关，其中最常见的是肾毒性。本研究的目的是评估伊朗癌症患者群体中顺铂的肾毒性。
2004年至2010年，所有接受顺铂治疗的肿瘤科室住院患者均纳入一项前瞻性研究。在基线和随访期间记录包括肾功能测试在内的临床和实验室数据。
共纳入100例患者（56%为男性）。他们的平均年龄为44岁。常见的不良事件为恶心（85%）和呕吐（78%），其次是厌食和疲劳（20%）、味觉改变（10%）、听力丧失（8%）、腹部绞痛（8%）和耳鸣（5%）。最重要的发现是肾功能正常，18%的患者有轻度低镁血症（1级毒性），但无任何症状或其他电解质异常。低镁血症患者均无明显血清电解质失衡、腹泻、严重过敏反应、行走困难或胸痛。
顺铂有产生轻度和重度副作用的可能性。虽然观察到神经和胃肠道毒性，但未观察到肾毒性（血尿素和肌酐升高或电解质异常），唯一的毒性是1级低镁血症。
